306results about How to "Inhibition of proliferative ability" patented technology

The invention discloses application of four kinds of known flavonoids compounds to treatment of breast cancers. The four kinds of known flavonoids are known compoundes obtained by separating fruit of sinopodophyllum emodi and have structures shown as structural formulas 1-4 in the specification. Experiments on the effect of the kinds of compounds on inhibiting human breast cancer cells show that the series of compounds have a favorable effect on inhibiting the proliferation of the breast cancer cells.

The present invention discloses application of ganoderic acid T and ganoderic acid Me in preparation of inhibitor of tumor growth or proliferation. The internal and external tests show that ganoderic acid T and ganoderic acid Me have obvious action for inhibiting human tumor cell growth or proliferation, at the same time its toxicity for normal cell is low.

The invention belongs to the field of pharmacy and tumor diagnosis and treatment, and particularly relates to a compound serving as a cyclin-dependent kinase 7 (CDK7) inhibitor, and application of thecompound in treatment of proliferative diseases such as cancers including breast cancer, ovarian cancer, colon cancer, liver cancer, lung cancer and glioma. The CDK7 small-molecule inhibitor is a compound with the structural general formulas (I)-(X), or a stereoisomer, a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, isotope labeled derivative or prodrug thereof. The small-molecule inhibitor provided by the invention is wide in anticancer spectrum; the compound has a good growth inhibition effect on various cancer cells such as liver cancer, stomach cancer, colorectal cancer, ovarian cancer, glioma, lung cancer and the like, provides an effective drug for preventing or treating proliferative diseases, especially cancers, in the aspects of structure and action mechanism, and has a good application prospect.

The invention belongs to the technical field of genetic engineering, and discloses long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs. Cancers include colorectal cancer, breast cancer, kidney cancer and the like. Expression of the long noncoding RNA SNHG15 in tumor tissues of patients suffering from the colorectal cancer, the breast cancer andthe kidney cancer is up-regulated. The patients with highly-expressed long noncoding RNA SNHG15 have poor prognosis. Through expression knock-down of the long noncoding RNA SNHG15 in colorectal cancercell lines, invasion, migration and multiplication capabilities of cells can be inhibited, and drug susceptibility of colorectal cancer cell lines to antitumor drugs including gemcitabine and cis-platinum can be improved.

The invention discloses applications of CIZI gene and relevant medicines, discloses applications of CIZI gene in preparation or screening of oncological therapeutic medicines of liver cancer, lung cancer, breast carcinoma or glioma, further constructs separated nucleic acid molecules, CIZI gene interference nucleic acid construction bodies and CIZI gene interference lentivirus which can decrease expression of CIZI gene in tumor cells and discloses applications thereof. The nucleic acid molecules, nucleic acid construction bodies or CIZI gene interference lentivirus can inhibit the expression of the CIZI gene specifically. Especially, lentivirus can infect target cells efficiently, the expression of the CIZI gene in the target cells is inhibited efficiently, furthermore the growth of the tumor cells is inhibited, the apoptosis of the tumor cells is promoted, and the applications of CIZI gene and the relevant medicines are significant in oncotherapy.

The invention relates to the fields of pharmacochemistry and pharmacotherapeutics and particularly relates to nitric oxide donor type coumarin derivatives, preparation methods therefor and an application of the nitric oxide donor type coumarin derivatives. The compounds play a role in resisting tumors and can be applied to the preparation of antitumor drugs.

The invention discloses an anti-PRRSV (porcine reproductive and respiratory syndrome virus) microRNA (ribonucleic acid)-like virus small RNA sequence and an application and detection method thereof. A sequence of a mature body of PRRSV-vsRNA1 and a precursor sequence as well as a secondary structure with encoding of PRRSV-vsRNA1 are disclosed. The inhibiting effect of the PRRSV-vsRNA1 in porcine alveolar macrophages (PAMs) infected by PRRSV and highly pathogenic strains of PRRSV is verified through different methods. The anti-PRRSV microRNA-like virus small RNA sequence can specifically target PRRSV viral non-structure protein 2(Nsp2), and function of proliferation of the PRRSV in PAMs is inhibited. The PRRSV-vsRNA1 is expected to be novel medicine for preventing and controlling PRRS, and the effective method is provided for prevention and control of the PRRSV.

The invention discloses an anti-VEGFR2 human source nano antibody NTV1 which comprises a frame region and a complementarity-determining region, wherein the nano antibody has an amino acid sequence shown in SEQ ID NO: 1. The invention further provides a preparation method for the anti-VEGFR2 human source nano antibody NTV1. The preparation method comprises the following steps: a, screening a nano antibody combined with VEGFR2 by adopting a phage display technology; b, carrying out expression and purification of the nano antibody; and c, determining the interaction between an antigen and the antibody by adopting an AlphaScreen technology to further screen the antibody with the highest affinity . The human source nano antibody NTV1 with higher affinity and good anti-tumor activity is obtained. The VEGFR2 nano antibody egg white which is high in affinity and stable and uniform is obtained by expression and optimization, a human source anti-VEGFR3 nano antibody drug is successfully developed, and a novel field of drug research and development of a targeted VEGFR2 antibody is opened up.

The invention relates to a method for separating and extracting C15H18O5 from Cichorium glandulosum Boiss.et Hout and use of C15H18O5 the English name of which is 11B, 13-Dihydrolacurin. The method is characterized by comprising the following steps: soaking the root of Cichorium glandulosum Boiss.et Hout by ethanol; collecting the percolate by a percolation method; obtaining a thick extract by a reduced pressure distillation device; passing the extract through a silicagel column, an octadecylsilyl column and a Sephadex LH-20 column; eluting; and drying the eluant by the reduced pressure distillation device to obtain dry powder which is the monomer C15H18O5, the English name of which is 11B, 13-Dihydrolacurin. The compound has the effect of preventing anti-hepatic fibrosis, namely, the compound inhibits activating and proliferating effect of hepatic stellate cells, so that the C15H18O5 with the English name of 11B, 13-Dihydrolacurin can be used as a lead compound for preventing anti-hepatic fibrosis.

The invention discloses applications a correlated medicament of a human STIM1 gene. The invention discloses applications of the human STIM1 gene in tumor treatment, tumor diagnosis and medicament preparation. The invention also further constructs a human STIM1 gene small-interfering ribonucleic acid (siRNA), a human STIM1 gene interfering nucleic acid construct, a human STIM1 gene interfering slow virus and applications thereof. The siRNA or nucleic acid construct and slow virus comprising the siRNA sequence can specifically inhibit the expression of the human STIM1 gene, particularly, the slow virus can infect a target cell efficiently so as to effectively inhibit the expression of STIM1 gene in the target cell, thus further inhibiting the growth of tumor cells and promoting apoptosis of the tumor cells. Therefore, the human STIM1 gene has important significance in tumor treatment.

The invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular relates to a neogambogic acid derivative, as well as a preparation method and a pharmaceutical application thereof. The neogambogic acid derivative has an anti-tumor function and can be used for preparing anti-tumor pharmaceuticals. The invention further relates to the preparation method of the neogambogic acid derivative.

The invention provides Holothuria moebii saponin A. The Holothuria moebii saponin A is prepared by separating total Holothuria moebii saponin from the marine invertebrate Holothuria moebii through percolation, extraction and reverse phase silica gel (ODS) column chromatography, then carrying out reverse phase silica gel column chromatographic separation and carrying out pressure-reduced concentration. The Holothuria moebii saponin A provided by the invention can substantially inhibit proliferation of a plurality of cells like rat brain glioma C6 and human brain glioma U87-MG, U251 and SHG-44, induce tumor cell apoptosis, reduce protein expression of a plurality of key enzymes in characteristic metabolism process of tumor cells and has a unique multi-target anti-glioma characteristic. Thus, the Holothuria moebii saponin A can be applied in preparation of drugs used for treating brain glioma. The chemical structural formula of the Holothuria moebii saponin A is described in the specification.

The invention discloses an application related pharmaceuticals of a human ubiquitin-protein ligase 138 (RNF138) gene and particularly discloses an application of the human RNF138 gene in tumor treatment and pharmaceutical preparation. The invention further structures an oligonucleotide molecule, a human RNF138 gene interference lentiviral vector and a human RNF138 gene interference lentivirus for human RNF138 gene separation and discloses applications thereof. The oligonucleotide molecule or the lentiviral vector and the lentivirus containing an oligonucleotide molecule sequence provided by the invention can specifically inhibit the human RNF138 gene expression, and particularly, the lentivirus can efficiently infect target cells, effectively inhibit the RNF138 gene expression of the target cells, further inhibit the tumor cell growth, promote the tumor cell apoptosis and have an important meaning on tumor treatment.

The invention belongs to the technical field of gene, and relates to an application of long-chain non-coding RNA BC009639 in preparing a preparation for inhibiting tumor cell migration. In the application, a long-chain non-coding RNA BC0009639 possibly closely related to tumor migration is screened and verified from a pair of lung cancer cell lines with different migration potency by using a genechip, proved by scratch experiment and Transwell experiment, the long-chain non-coding RNA BC0009639 can inhibit migration of tumor cells, and proved by MTT experiment, the long-chain non-coding RNA BC0009639 can inhibit the multiplication capacity of the cells; the experiment results verify that the long-chain non-coding RNA BC009639 can inhibit the migration of tumor cells and inhibit the multiplication capacity of the cells; the sequence of the long-chain non-coding RNA BC0009639 is closely related to 3'UTR of an IMPAD1 mRNA sequence, and the expression is affected by gambogic acid and is in negative correlation with the survival rate of tumor cells. The invention provides basic theory foundation and research data for exploring the action mechanism of the long-chain non-coding RNA BC0009639 to an organism and correlation and directed treatment of clinical diseases.

The invention discloses a substituted 2,3-dihydro-4(1H)- quinazolone derivative shown in the formula I, pharmaceutically acceptable salt or solvate and a drug composite containing the same and application thereof. The compound has very good effect of restraining vascular endothelial cell proliferation. The compound, the pharmaceutically acceptable salt or solvate or the drug composite containing the same can be used for drugs requiring to restraining angiogenesis diseases and/or cytotoxicity exerting diseases.